The area under the curve (AUC ) of drug concentration versus time can be associated with the therapeutic or toxic effect of a drug.
MATERIALS AND METHODS

Simulation of Blood Concentration of Hypothetical Drugs
We simulated the blood concentration of hypothetical drugs, the pharmacokinetics of which is described by a 1-compartment model with first-order absorption.
6) The true jth drug concentration (C* ij ) in the i-th individual at a specific time (t ij ) after the last dose following repetitive oral administration is described as follows: (1) where D i is the dose in the i-th individual, and t i is the dosing interval in the i-th individual. The absorption rate constant of a drug in the i-th individual (ka i ) is described as follows:
where ka is the population mean of the absorption rate constant, and h ka,i is a random variable distributed normally with a mean of zero and variance of w 2 ka . The absorption lag-time in the i-th individual (ALAG i ) is described as follows:
where ALAG is a population mean of the absorption lag-time, and h ALAG,i is a random variable distributed normally with a mean of zero and variance of w 2 ALAG . Similarly, the elimination rate constant of a drug in the i-th individual (ke i ) is described as follows: The area under the curve (AUC) can be associated with the therapeutic or toxic effect of a drug. The limited sampling model (LSM) is an approach that is gaining popularity due to its simplicity for the estimation of AUC using 1-3 blood samples. The aim of the present simulation study was to compare the performance of LSM for various hypothetical drugs with that of the naive trapezoidal method (Trap). The 3-point (trough, peak, and downhill) sampling design following repetitive oral dosing was assumed for LSM (LSM3) and Trap (Trap3). The 2-point (trough and peak) sampling design was also assumed for LSM (LSM2) and Trap (Trap2). In addition, trough-sampling and peak-sampling designs for LSM were designated as LSM1 and LSM1, respectively. As a result, the rank order of precision of the AUC estimation designs/methods was summarized as follows: LSM3ϷTrap3ՆLSM2ՆTrap2ϷLSM1ϾLSM1. The finding suggested that LSM can not always improve the estimation performance of AUC in the 3-point sampling design, and that LSM1 is insufficient to estimate the performance of AUC for the hypothetical drugs evaluated in the present study. Accordingly, LSM2 and LSM1 may be an efficient approach for estimating AUC following repetitive oral dosing. In addition, Trap3 and Trap2 may be promising alternatives, because Trap does not require a high investment to recruit a full-sampling modeldevelopment group.
where CL/F i is oral clearance in the i-th individual, CL/F is a population mean of oral clearance, and h CL/F,i is the random variable distributed normally with a mean of zero and variance of w 2 CL/F . V/F i is the apparent volume of distribution in the i-th individual, V/F is a population mean of the apparent volume of distribution, and h V/F,i is the random variable distributed normally with a mean of zero and variance of w 2 V/F . Finally, the j-th measured drug concentration in the i-th individual (C ij ) at t ij is described as follows:
where e ij is a random variable distributed normally with a mean of zero and variance of s 2 . Table 1 summarizes the ka, ALAG, V/F, CL/F, w ka , w ALAG , w CL/F , w V/F , and s values of 4 hypothetical drugs evaluated in the present study. In addition, D i and t i were assumed to be 1 and 12, respectively, for all hypothetical drugs. Figure 1 shows the blood drug concentration in a typical individual with population mean pharmacokinetic parameters (ka,
ALAG, CL/F, and V/F).
LSM for Hypothetical Drugs The 3-point (trough, peak, and downhill) sampling design at steady state following repetitive oral dosing was assumed for LSM (LSM3). The 2-point (trough and peak) sampling design was also assumed for LSM (LSM2). In addition, trough-sampling and peak-sampling designs for LSM were designed as LSM1 and LSM1Ј, respectively.
LSM3 was calculated from the data obtained from the fullsampling model-development group (nϭ25) using the following regression model:
where AUC Trap8 is the AUC value obtained by the standard linear trapezoidal method using 8 drug concentration data (Trap8). C trough , C peak , and C downhill are the observed trough, peak, and downhill drug concentration, respectively, and a, b, c, and d are the model parameters to be estimated. Table 2 shows the sampling time of LSM3 and Trap8 for 4 hypothetical drugs. LSM2 was also calculated from the data obtained from the full-sampling model-development group (nϭ25) using the following regression model:
Similarly, LSM1 was calculated using the following regression model:
In addition, LSM1Ј was calculated using the following regression model: each LSM were evaluated using the data obtained from another validation group (nϭ100). The percentage error (% error) of the estimated AUC in each subject was computed as follows: % errorϭ(estimated valueϪtrue value)/true valueϫ100. The accuracy of the estimated AUC was judged by the mean (over the 100 subjects) of % error, and the precision by the standard deviation of % error. In the present study, we compared the estimation performance of LSM for 4 hypothetical drugs with that of the naive trapezoidal method. In addition to Trap8, we assumed 3 kinds of the linear trapezoidal method (Trap2, 3, and 4) for each hypothetical drug. Table 2 summarizes the sampling time in Trap2, 3, and 4, where the drug concentration at time 12 is assumed to be the same as that at time 0. All simulation and analysis were performed by use of Microsoft ® Excel (Tokyo, Japan).
RESULTS AND DISCUSSION
In the present simulation study, we compared the AUC estimation performance of LSM for 4 hypothetical drugs with that of naive Trap. We assumed Drug A with a mean t 1/2,ka (0.693/ka) of 1, and with a mean t 1/2,ke (0.693/ke) of 12 ( Table  1) . The mean time to reach maximal drug concentration (t max ) after the last dose of Drug A was 2.8. In addition, we assumed Drug B with a mean t 1/2,ka of 1, a mean t 1/2,ke of 8, a mean ALAG of 0.4, and a mean t max of 3.1 (Table 1) . Therefore, the sampling time of C trough , C peak , and C downhill for Drug A and B was designed to be 0, 3, and 6, respectively (Fig. 1) . We further assumed Drugs C and D with t 1/2,ke of 4, which is considerably short relative to t i of 12 (Fig. 1) . The mean t max of Drugs C and D was 1.9; hence, the sampling time of C trough , C peak , and C downhill for Drugs C and D was designed to be 0, 2, and 6, respectively (Fig. 1) . In addition, the w values of Drug D were larger than those of Drug C (Table 1) .
We first developed LSM3, 2, 1, and 1Ј using the full-sampling drug concentration data obtained from the model development group (nϭ25), and preliminarily evaluated the AUC estimated by LSM (AUC LSM ) for 4 hypothetical drugs. Figure  2 shows the LSM equation, the correlation between AUC Trap8 and AUC LSM , and also the R 2 value. The R 2 values for LSM3 ranged from 0.898 to 0.980 for 4 hypothetical drugs, indicating that AUC LSM3 was highly correlated with AUC Trap8 . In addition, the R 2 values for LSM2 ranged from 0.860 to 0.955, which were only slightly lower than those for LSM3. On the other hand, the R 2 values for LSM1 ranged from 0.757 to 0.900, whereas those for LSM1Ј were considerably low and ranged from 0.258 to 0.796 (Fig. 2) .
We then evaluated the accuracy (precision) of the estimated AUC LSM and the AUC estimated by Trap (AUC Trap ) for 4 hypothetical drugs, using another validation group (nϭ100). In the present simulation study, we defined the true AUC in each subject as D i /(CL/F i ), and calculated % error of the estimated AUC. Figure 3 shows the mean (ϮS.D.) % error of the estimated AUC LSM and AUC Trap for 4 hypothetical drugs. The accuracy (precision) of AUC Trap4 was fairly good for 4 hypothetical drugs, and was similar to that of LSM3 (Fig. 3) . The rank order of precision of 1-3 sampling designs/methods for AUC estimation was summarized as follows: LSM3ϷTrap3ՆLSM2ՆTrap2ϷLSM1ϾLSM1Ј. That is, the accuracy (precision) of AUC Trap3 was comparable to that of AUC LSM3 for 4 hypothetical drugs (Fig. 3) . The results suggested that the estimation performance of AUC LSM3 is not always superior to that of AUC Trap3 , although the LSM method is expensive to recruit a full-sampling model-development group. The accuracy and precision of AUC Trap2 were comparable to those of AUC LSM2 for Drugs A and B, whereas the estimation performance of LSM2 seemed to be better than those of Trap2 for Drugs C and D (Fig. 3) . The findings may be consistent with our previous reports; that is, AUC Trap2 (or CL/F) was accurate for drugs with a t 1/2,ke comparative to or longer than t i , whereas the accuracy of AUC Trap2 (or CL/F) deteriorated for drugs with a short t 1/2,ke relative to t i . 6,7) In 1-point sampling designs, the estimation performance of AUC LSM1Ј was inferior to that of AUC LSM1 for 4 drugs tested in the present study (Fig. 3) .
In conclusion, the present simulation study suggested that LSM can not always improve the estimation performance of AUC in the 3-point sampling design, and that LSM1Ј was insufficient in the estimation performance of AUC for the hypothetical drugs evaluated in the present study. Accordingly, LSM2 and LSM1 may be efficient approaches to estimate AUC following repetitive oral dosing. In addition, Trap3 and Trap2 may be promising alternatives, because Trap is not expensive to recruit a full-sampling model-development group. The accuracy and precision of limited sampling strategies to estimate AUC for a target drug of individual researchers should be evaluated carefully by computer simulation prior to a real clinical trial.
